生物医药板块盘初普升 复宏汉霖(02696)涨7.96% 机构指中国创新药进入全球价值兑现阶段

金吾财讯
Sep 21

金吾财讯 | 港股生物医药板块盘初普升,截至发稿,复宏汉霖(02696)涨7.96%,诺诚健华(09969)涨7.34%,荣昌生物(09995)涨6.69%,康诺亚-B(02162)涨6.52%,康方生物(09926)涨6.46%,君实生物(01877)涨6.41%,金斯瑞生物科技(01548)涨5.80%,科伦博泰生物(06990)涨5.63%,药明生物(02269)涨4.47%,药明康德(02359)涨2.90%,泰格医药(03347)涨2.69%,百济神州(06160)涨2.07%,药明合联(02268)涨1.75%。消息面上,近日有关部门联合发布《医药工业发展“十五五”规划》。其中提出,2030年,规模以上医药工业企业营业收入将超过3.5万亿元;产业规模效益稳步提升,创新药产业规模增速年均达到20%以上,全球年销售额超10亿美元的品种数量达到5个以上。中信证券表示,中国创新药进入全球价值兑现阶段,头部国际化创新药企业有望迎来产品全球价值兑现期。此外,头部创新药企业产品放量进入新的成长阶段,具有全球潜力的管线资产国际化有望加速兑现。开源证券认为,国内原料药行业逐渐企稳回升,部分公司积极布局创新药赛道,持续拓展公司天花板,有望进入收获期。国内血制品行业处于周期底部,行业并购整合加速进行中。疫苗行业加速布局新品及创新技术。国内医疗服务板块受政策影响较大,行业处于出清阶段,部分品牌强、运营能力强的公司有望率先走出困境。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10